The United States Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application for United States-based Lannett Company Inc's (NYSE: LCI) Dronabinol Capsules USP, 2.5mg, 5mg and 10mg, it was reported yesterday.
For the 12 months ended March 2018, total US sales of Dronabinol Capsules USP, 2.5mg, 5mg and 10mg, was around USD120m, according to IMS.
Tim Crew, chief executive officer of Lannett, said, 'The approval of Dronabinol Capsules adds to our sizeable portfolio of near-term product opportunities. We expect to commence marketing several products including Dronabinol Capsules over the course of this year. Currently, only a handful of manufacturers supply generic Dronabinol Capsules to the US market.'
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT